OncoMatch/Clinical Trials/NCT06517511
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Is NCT06517511 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Selinexor Oral Tablet [Xpovio] and R-CHOP Protocol for diffuse large b cell lymphoma.
Treatment: Selinexor Oral Tablet [Xpovio] · R-CHOP Protocol — This is a prospective, single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of selinexor in combination with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) followed by selinexor maintenance for untreated TP53-mutated diffuse large B-cell lymphoma (DLBCL) patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: TP53 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: systemic anti-lymphoma therapy
Exception: prior local radiotherapy alone is permitted
No prior systemic anti-lymphoma therapy; prior local radiotherapy alone is permitted.
Cannot have received: XPO1 inhibitor
The patients had previously received XPO1 inhibitors.
Lab requirements
Blood counts
adequate function of bone marrow
Kidney function
adequate function of kidney
Liver function
adequate function of liver
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06517511 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require TP53?
Yes, TP53 mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify